Patent intelligence · EP
EP 1392755
ZUSAMMENSETZUNGEN ENTHALTEND LIPID-POLYMER KONJUGATE
ZUSAMMENSETZUNGEN ENTHALTEND LIPID-POLYMER KONJUGATE
Patent details — EP 1392755
- Jurisdiction
- EP
- Status
- expired
- Grant date
- Mar 3, 2004
- Expiration
- Feb 27, 2024
- Applicant
- YAMANOUCHI EUROP BV [NL]
- CPC classes
- A61K 9/ 127 A I, A61K 47/ 08 A I, A61K 47/ 10 A I, A61K 47/ 12 A I
Quick answer
EP 1392755 (ZUSAMMENSETZUNGEN ENTHALTEND LIPID-POLYMER KONJUGATE) is held by YAMANOUCHI EUROP BV [NL]. Status: expired. Granted Mar 3, 2004. Expires Feb 27, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- YAMANOUCHI EUROP BV [NL]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 127 A I, A61K 47/ 08 A I, A61K 47/ 10 A I, A61K 47/ 12 A I, A61K 47/ 16 A I, A61K 47/ 18 A I
More from YAMANOUCHI EUROP BV [NL]
Related pharmaceutical patents in our USPTO index.
-
CN 120418289
Combination therapy of bispecific binding agents that bind to CLDN18.2 and CD3 with immune checkpoint inhibitors
granted -
KR 20240032847
CLDN18.2 및 CD3에 결합하는 이중특이 결합제
granted -
CN 105120840
Composition of tiacumicin compounds
granted -
EP 1549658
VERBINDUNGEN AUF GLUKOSEBASIS MIT AFFINITÜT FÜR P-SELEKTIN
expired -
EP 1527086
VERBINDUNGEN DIE P-SELECTIN BINDEN
expired -
EP 1423413
SELEKTIV P-SELECTIN BINDENDE PEPTIDISCHE VERBINDUNGEN
expired -
IS 5505
Notkun á blöndu díóls og alfa-hýdroxýsýru til að meðhöndla sjúkdóma sem lýsa sér í ofvexti í hornlagi húðþekju
expired
Frequently asked questions
What is US patent 1392755?
EP 1392755 (ZUSAMMENSETZUNGEN ENTHALTEND LIPID-POLYMER KONJUGATE) is held by YAMANOUCHI EUROP BV [NL]. Status: expired. Granted Mar 3, 2004. Expires Feb 27, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 1392755?
YAMANOUCHI EUROP BV [NL] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does EP 1392755 expire?
Our index shows an expiration date of Feb 27, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.